NUTRITIONAL COMPOSITIONS AND INFANT FORMULAS CONTAINING OLIGOFRUCTOSE FOR REDUCING THE LOAD OF PATHOGENIC BACTERIA IN THE GUTS OF INFANTS AND YOUNG CHILDREN
The invention relates to a nutrition composition with oligofructose and optionally high sn-2 palmitate for down regulating, decreasing or inhibiting the growth of pathogenic bacterial populations in the guts of infants or young children. The infants can be 0-12 months of age and the composition can be an infant formula. Higher dosage of oligofructose intensifies the effect. The composition promotes a healthy intestinal microbiota.
1 . A method for down-regulating, decreasing or inhibiting the growth of pathogenic bacteria in the gut of infants or young children in need of same comprising administering a nutritional composition selected from the group consisting of:
at least 0.4 g or at least 0.7 g Oligofructose/100 kcal of the nutritional composition;
at least 3 g/L or at least 5 g/L of Oligofructose when the composition is a ready-to-drink liquid composition; and
a sufficient amount of oligofructose to obtain respectively at least 3 g/L or 5 g/L of oligofructose in the reconstituted composition when the nutritional composition is a powered or concentrated composition.
2 . The method of claim 1 wherein the infants are born at term.
3 . The method of claim 1 wherein the infants are 0 to 12 months of age.
4 . The method of claim 1 wherein at last 90% of the oligofructose have a degree of polymerisation between 2 and 8.
5 . The method of claim 1 wherein the composition comprises triglycerides with high sn-2 palmitate.
6 . The method of claim 1 wherein the composition comprises fat and at least 8% of the fat is sn-2 palmitate.
7 . The method of claim 1 wherein the composition is an infant formula or a follow-on formula.
8 . The method of claim 1 wherein the composition comprises alpha-lactalbumin proteins in an amount of at least 0.3 g/100 kcal or 2.3 g/L of composition.
9 . The method of claim 1 wherein the pathogenic bacteria are selected from the group consisting of Klebsiella pneumoniae, E. coli , Enteropathogenic E. coli, Clostridium difficile and/or Clostridium perfringens.
10 . The method of claim 1 wherein the down-regulation, decrease or inhibition the growth of pathogenic bacteria is measurable in infants stools.
11 . The method of claim 1 wherein the composition is fed or intended to be fed during the first 4 weeks of life.
12 . The method of claim 1 wherein the infants have a characteristic selected from the group consisting of born prematurely, born by caesarean section, exhibit unbalanced or abnormal intestinal microbiota and suffer from intestinal infection.
13 . The method of claim 1 wherein the down-regulation, decrease or inhibition the growth of pathogenic bacteria in the gut of infants or young children further induces the gut microbiota of the infants or young children to be more similar to the microbiota of exclusively breast-fed infants or young children than microbiota of infants fed from a conventional composition not containing said oligofructose.
14 . The method of claim 1 wherein the composition has a characteristic selected from the group consisting of
less than 1 g or less than 2 g Oligofructose/100 kcal of said nutritional composition;
less than 10 g/L or less than 15 g/L of Oligofructose when said composition is a ready-to-drink liquid composition; and
a sufficient amount of oligofructose to obtain respectively less than 10 g/L or less than 15 g/L of oligofructose in the reconstituted composition when the nutritional composition is a powered or concentrated composition.